# Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors

> **NCT06175780** · PHASE1 · UNKNOWN · sponsor: **Novatim Immune Therapeutics (Zhejiang) Co., Ltd.** · enrollment: 189 (estimated)

## Conditions studied

- Neoplasms
- Neoplasms by Histologic Type

## Interventions

- **DRUG:** KY-0118
- **DRUG:** KY-0118
- **DRUG:** KY-0118

## Key facts

- **NCT ID:** NCT06175780
- **Lead sponsor:** Novatim Immune Therapeutics (Zhejiang) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-28
- **Primary completion:** 2025-12-28
- **Final completion:** 2025-12-28
- **Target enrollment:** 189 (ESTIMATED)
- **Last updated:** 2023-12-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06175780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06175780, "Phase I Study of KY-0118 in Subjects With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06175780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*